What it sells
Atlas Bio runs in silico clinical trials in immunology using a foundation AI model of human biology to predict and compare patient responses across treatments and indications.
Business model breakdown
Trigger: what makes them buy now?
Deciding which development path to back before committing to a trial, e.g. prioritising indications or in-licensing go/no-go decisions.
Distribution: how it reaches customers
"Discuss an asset" contact; project-based engagements.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-10-28 | — | $12.5M | — | news.google.com |
| 2026-10-27 | — | $10M | — | news.google.com |
| 2026-10-27 | — | $12.5M | — | tech.eu |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-29.